Company Overview - Baipusais announced a 2024 distribution plan, proposing a 10-for-4 stock split and a cash dividend of 4 yuan (including tax), with a total cash payout of 47.906 million yuan, accounting for 38.69% of net profit, marking the fifth cash distribution since the company's listing [2][10] - The company reported a revenue of 645 million yuan for the year, representing a year-on-year increase of 18.65%, while net profit decreased by 19.38% to 124 million yuan, with basic earnings per share at 1.0319 yuan and a weighted average return on equity of 4.8% [2] Industry Context - In the pharmaceutical and biotechnology sector, 153 companies have announced their 2024 distribution plans, with WuXi AppTec leading in cash distribution at 7.692 billion yuan, followed by Yunnan Baiyao and Hengrui Medicine with 2.114 billion yuan and 1.275 billion yuan respectively [4] - The cash distribution ranking within the industry shows Baipusais' payout of 47.906 million yuan, with a net profit distribution ratio of 38.69% and a dividend yield of 0.98% [10]
百普赛斯2024年度拟派4790.6万元红包